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Background:The IRF6 transcription factor is critical for epithelial barrier function; however, a role for IRF6 in signaling by
Toll-like receptors has not been addressed.
Results: The IRAK1-mediated activation of IRF6 promotes TLR2-dependent CCL5 chemokine gene expression in epithelial
cells.
Conclusion: IRF6 differentially regulates TLR2 inflammatory responses in epithelial cells.
Significance:Our results reveal an additional immune-related function for IRF6.
Epidermal and mucosal epithelial cells are integral to host
defense. They not only act as a physical barrier but also utilize
pattern recognition receptors, such as the Toll-like receptors
(TLRs), to detect and respond to pathogens. Members of the
interferon regulatory factor (IRF) family of transcription factors
are key components of TLR signaling as they impart specificity
to downstream responses. Although IRF6 is a critical regulator
of epithelial cell proliferation anddifferentiation, its role inTLR
signaling has not previously been addressed.We show here that
IRF6 is activated by IRAK1 as well as byMyD88 but not by TRIF
or TBK1. Co-immunoprecipitation experiments further dem-
onstrated that IRF6 can interact with IRAK1. Gene silencing in
epithelial cells along with gene promoter reporter assays
showed that IRAK1 mediates TLR2-inducible CCL5 gene
expression at least in part by promoting IRF6 activation. Con-
versely, IRAK1 regulated CXCL8 gene expression independ-
ently of IRF6, thus identifying amolecular mechanism by which
TLR2 signaling differentially regulates the expression of specific
chemokines in epithelial cells. Bioinformatics analysis and
mutagenesis-based experiments identified Ser-413 and Ser-424
as key regulatory sites in IRF6. Phosphomimetic mutation of
these residues resulted in greatly enhanced IRF6 dimerization
and trans-activator function. Collectively, our findings suggest
that, in addition to its importance for epithelial barrier function,
IRF6 also contributes to host defense by providing specificity to
the regulation of inflammatory chemokine expression by TLR2
in epithelial cells.
Epidermal and mucosal epithelial cells are positioned at
the interface between the host and the environment and thus
play pivotal roles in host defense. Although one of their pri-
mary functions is to provide a physical barrier to pathogen
invasion (1, 2), they also express pattern recognition recep-
tors (e.g. Toll-like receptors), thereby enabling them to
actively participate in host defense by functioning as
immune sentinels (2–5). For example, the production of
inflammatory cytokines, chemokines, and type I interferons
(IFNs)5 by epithelial cells serves to recruit and activate dif-
ferent leukocyte cell populations. However, the dysregulated
production of such factors can lead to pathologic states of
chronic inflammation, as occurs in inflammatory bowel dis-
ease, psoriasis, and chronic periodontitis (6–8). Chronic
mucosal inflammation is also an important factor in some
cancers (e.g. gastric cancer) (9).
Toll-like receptors (TLRs) are fundamental to the detection
and subsequent host response to pathogens (10, 11). The spec-
ificity of TLR signaling is determined, in part, by differential use
of adapter proteins, for example, MyD88 and TRIF. Accord-
ingly, TLR signaling can be broadly divided into theMyD88-de-
pendent andTRIF-dependent pathways. The former pathway is
used by all TLRs with the exception of TLR3 and the latter only
by TLR3 and TLR4 (10, 11). The MyD88-dependent pathway
employs the protein kinase IL-1 receptor-associated kinase-1
(IRAK1) to trigger the activation of various transcription fac-
tors, including NF-B and members of the interferon regula-
tory factor family (e.g. IRF5 and IRF7), resulting in inflamma-
tory gene expression. The induction of inflammatory gene
expression by the TRIF-dependent pathway occurs in response
to the activation of IRF3 by TBK1 along with TAK1-mediated
NF-B activation (10–12).
In addition to regulating type I IFN (e.g. IFN) gene expres-
sion, IRFs also play important roles in regulating the expression
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of other inflammatory proteins, including chemokines (e.g.
CCL5, CXCL8, and CXCL10) (12–17). Consequently, the dif-
ferential regulation of inflammatory gene expression by IRFs
allows them to appropriately shape the immune response by
imparting signaling specificity to TLRs. The activation of IRF3
by TLR3 and TLR4 signaling, for instance, enables these recep-
tors to initiate TLR3- and TLR4-specific gene expression
responses (18, 19). Analogously, IRF5 and IRF7 induce specific
gene expression responses downstream of MyD88-dependent
TLRs (20–22).
Prior studies have largely focused on the roles of IRFs in
mediating TLR-elicited responses in leukocyte cell populations
(e.g. macrophages and dendritic cells). Although IRF3 has also
been shown to be important for TRIF-dependent TLR
responses in epithelial cells (23–25), the IRF(s) that mediates
MyD88-dependent responses in these cells is less clear. In con-
trast to other IRFs, IRF6 expression appears for themost part to
be limited to epithelial cells (26–30), where at least one func-
tion is to regulate cell proliferation and differentiation (27–29,
31, 32). Notably, IRF6-deficient mice exhibit defective epider-
mal barrier function due to impaired keratinocyte differentia-
tion; they also die perinatally (28, 29). Given the key roles of
other IRFs in orchestrating the TLR-elicited inflammatory
responses of leukocytes (12, 13), we investigated whether IRF6
was similarly important for specific TLR responses in epithelial
cells. Our findings here link IRF6 to IRAK1-dependent TLR2
responses (e.g.CCL5 expression) in epithelial cells, thus reveal-
ing an additional immune-related function for IRF6 in these
cells.
EXPERIMENTAL PROCEDURES
Reagents—Cell culture medium and supplements, fetal calf
serum (FCS), SuperScript III reverse transcriptase, random
primers, deoxyribonucleotide triphosphates, TaqMan Univer-
sal Master Mix II, Lipofectamine RNAiMAX, precast 10%
NuPAGE gels, mouse anti-V5 antibodies (HRP-conjugated and
unconjugated), Alexa Fluor 488-conjugated goat anti-rabbit
IgG antibody, andProLongGoldAntifade reagent (containing
4,6-diamidino-2-phenylindole) were from Invitrogen. Recom-
binant human CSF-1 was generously provided by Chiron.
Restriction enzymes were from New England Biolabs, whereas
PfuDNApolymerase, Passive Lysis Buffer, and theDual-GloTM
luciferase assay system were from Promega. PCR primers were
synthesized by GeneWorks. FuGENE 6TM and CompleteTM
protease inhibitors were supplied by Roche Applied Science.
The ON-TARGETplus IRF6 and IRAK1 siRNAs as well as the
control non-targeting siRNA were from Dharmacon. TLR
ligands were from InvivoGen. The rabbit anti-IRF6 antibody
and HRP-conjugated mouse anti-HA antibody were from Cell
Signaling, and the mouse anti-HSP90 antibody was from BD
Biosciences.
Cell Culture—OKF6/TERT-2 cells (33) were cultured in
keratinocyte serum-free medium supplemented with 25 g/ml
bovine pituitary extract, 2 ng/ml EGF, 0.4mMCaCl2, 100 units/ml
penicillin, 100 g/ml streptomycin, and 2 mM GlutaMax-1TM.
AGSandMKN28cellswere cultured inRPMI1640 supplemented
with 10% FCS, 100 units/ml penicillin, 100 g/ml streptomycin,
and 2 mM GlutaMax-1TM. HT-29 cells were cultured in McCoy’s
5Amedium supplementedwith 10% FCS, 100 units/ml penicillin,
100 g/ml streptomycin, and 2 mM GlutaMax-1TM. HEK293T
cells were cultured in Dulbecco’s-modified Eagle’s medium sup-
plemented with 10% FCS, 100 units/ml penicillin, 100 g/ml
streptomycin, and 2 mM GlutaMax-TM. Human monocytes were
purified from buffy coats (Red Cross Blood Bank, Australia) using
a RosetteSep antibodymixture (StemCell Technologies) followed
by Ficoll-Paque density gradient centrifugation. The monocytes
were cultured overnight in RPMI 1640 supplemented with 10%
FCS, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM
GlutaMax-TM. Monocyte-derived macrophages were generated
by culturing monocytes in the presence of CSF-1 (2500 units/ml)
for 6–8 days (34). All cells were cultured at 37 °C in a humidified
atmosphere of 5% CO2.
Real-time PCR—Total RNA was purified using an RNAeasy
Mini kit (Qiagen). RNA (1 g) was reverse-transcribed into
cDNA using random primers and SuperScript III reverse tran-
scriptase. Real-time PCR was performed (in triplicate) using an
Applied Biosystems Prism 7900HT sequence detection system
and pre-developed TaqMan assays (Invitrogen) for the follow-
ing genes:CCL5 (Hs00174575_m1),CXCL8 (Hs00174103_m1),
IFN (Hs02621180_s1), IRAK1 (Hs01018347_m1), IRAK2
(Hs00176394_m1),IRF3(Hs00155574_m1),IRF5(Hs00158114_
m1), IRF6 (Hs00196213_m1), IRF7 (Hs00185375_m1), TLR1
(Hs00413978_m1), TLR2 (Hs00152932_m1), TLR3 (Hs01551078_
m1), TLR4 (Hs01060206_m1), TLR5 (Hs00152825_m1), TLR6
(Hs00271977_s1),TLR7 (Hs01933259_s1),TLR8 (Hs00607866_
mH), and TLR9 (Hs00370913_s1). Messenger RNA levels, rel-
ative to those of the endogenous control gene,HPRT, were cal-
culated using the Ct (cycle threshold) method.
Expression Vectors and Site-directed Mutagenesis—The
human IRF6 expression vector, pCMV6-XL6-IRF6, was pur-
chased from Origene. The expression vector, pEF-HA-IRF6
(expresses an N-terminal HA-tagged version of IRF6), was cre-
ated by PCR using the primer pair F1 (5-CG ACG CGT GCC
CTC CAC CCC CGC AGA GTC CGG CTA AAG-3) and R1
(5-CG ACG CGT TTA CTG GGG AGG CAG GGC AGG
GGG CAG TTG-3) and pCMV6-XL6-IRF6 as the template.
The PCR product was digested with MluI and cloned into the
expression vector, pEF-HA. The expression vector, pEF-V5-
IRF6 (expresses an N-terminal V5-tagged version of IRF6), was
created by excising the cDNA insert from pEF-HA-IRF6 with
MluI and cloning it into pEF-V5. The expression vector, pEF-
HA-IRF6 S413A (Ser-413 replaced by alanine), was created by
overlapping PCR using the primer pairs F1 and R2 (5-ACT
GCCACTATCAAAGGCTCGTGTGAAATCACC-3) and
F2 (5-GGT GAT TTC ACA CGA GCC TTT GAT AGT GGC
AGT-3) and R1 and pCMV6-XL6-IRF6 as the template. The
expression vector, pEF-HA-IRF6 S424A (Ser-424 replaced by
alanine), was created using the primer pairs F1 and R3 (5-CTT
GAT GTC TGG GGT TGC GAT CTG CAG GCG GAC-3)
and pairs F3 (5-GTC CGC CTG CAG ATC GCA ACC CCA
GACATCAAG-3) and R1 and pCMV6-XL6-IRF6 as the tem-
plate. The expression vector, pEF-HA-IRF6 S413A/S424A
(Ser-413 and Ser-424 replaced by alanine), was created using
the primer pairs F1 and R3 and pairs F3 and R1 and pEF-HA-
IRF6 S413A as the template. The expression vector, pEF-HA-
IRF6 S413E (Ser-413 replaced by glutamic acid), was created
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using the primer pairs F1 and R4 (5-ACT GCC ACT ATC
AAA TTC TCG TGT GAA ATC ACC-3) and pairs F4 (5-
GGT GAT TTC ACA CGAGAA TTT GAT AGT GGC AGT-
3) and R1 and pCMV6-XL6-IRF6 as the template. The expres-
sion vector, pEF-HA-IRF6 S424E (Ser-424 replaced by glutamic
acid), was created using the primer pairs F1 and R5 (5-CTT
GAT GTC TGG GGT TTC GAT CTG CAG GCG GAC-3)
and pairs F5 (5-GTC CGC CTG CAG ATC GAA ACC CCA
GACATCAAG-3) and R1 and pCMV6-XL6-IRF6 as the tem-
plate. The expression vector, pEF-HA-IRF6 S413E/S424E (Ser-
413 and Ser-424 replaced by glutamic acid), was created using
the primer pairs F1 and R5 and pairs F5 and R1 and pEF-HA-
IRF6 S413E as the template. The expression vector, pEF-V5-
IRF6 S413E/S424E (expresses anN-terminal V5-tagged version
of IRF6 S413E/S424E), was created by excising the cDNA insert
from pEF-HA-IRF6 S413E/S424E withMluI and cloning it into
pEF-V5. The IRAK1 expression vectors, pEF-V5-IRAK1 and
pEF-V5-IRAK1 K239A (express V5-tagged versions of wild
type and kinase-dead IRAK1, respectively), are as previously
described (35, 36). The IRAK2 expression vector was a gener-
ous gift from Dr. Luke O’Neill (Trinity College, Ireland),
whereas the MyD88, TBK1, and TRIF expression vectors were
kindly provided by Dr. Ashley Mansell (Monash Institute of
Medical Research, Australia).
GenePromoter ReporterAssays—HEK293T cellswere seeded
in 12-well tissue culture plates at a density of 3 105 cells per
well and transfected (in duplicate) the next day using FuGENE
6TM transfection reagent. The total amount of plasmid in each
transfection was kept constant by using empty vector where
required. The cells were lysed 24 h post-transfection with Pas-
sive Lysis Buffer and assayed for firefly and Renilla luciferase
activities using the Dual-Glo™ luciferase assay system. Renilla
luciferase activity was used to normalize transfection efficien-
cies. The luciferase-based CCL5 (37), CXCL8 (38), and IFN
and IFN4 gene promoter reporter plasmids were generously
provided by Drs. Paula Pitha (Johns Hopkins University), Allan
Brasier (University of TexasMedical Branch), andAshleyMan-
sell (Monash Institute of Medical Research, Australia), respec-
tively. The Renilla luciferase reporter plasmid, pRL-TK, was
from Promega.
Silencing of IRAK1 and IRF6 Expression—Areverse-transfec-
tion protocol was used for siRNA transfections. Briefly, the
IRAK1- and IRF6-targeting siRNAs as well as the control non-
targeting siRNA were diluted to 120 nM with 100 l of Opti-
MEM I-reduced serum medium (Invitrogen). The diluted
siRNAwasmixed with 100l of Opti-MEM I-reduced serum
medium containing 1.0 l of Lipofectamine RNAiMAX
transfection reagent and incubated at room temperature for
20 min. OKF6/TERT-2 cells (2  105 cells in 1.0 ml of anti-
biotic-free growth medium) were plated into 12-well plates,
and the transfection mixture then added. The medium was
replaced 24 h later, and the cells were analyzed or stimulated
48 h post-transfection.
Cell Lysis and Western Blotting—Cells were washed twice
with ice-cold PBS and then lysed (20mMTris-HCl (pH 7.4), 150
mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 10% glycerol, 10 mM
-glycerol phosphate, 10 mM NaF, and CompleteTM protease
inhibitors) on ice for 60 min. The lysates were clarified by cen-
trifugation (13,000  g for 10 min at 4 °C), and the protein
concentrations measured using a protein assay kit (Bio-Rad).
Cell lysates were subjected to electrophoresis on 10%NuPAGE
gels followed byWestern blotting according to standard proto-
cols. Immunoreactive bands were visualized using ECL
reagents (Millipore) and a LAS-3000 Imager (Fujifilm) or by
exposure to x-ray film (Fujifilm). Films were scanned using a
GS-800 Calibrated Imaging Densitometer (Bio-Rad).
In Vitro Protein Dephosphorylation Assay—Transfected
HEK293T cells were lysed as above, except phosphatase inhib-
itors were omitted from the lysis buffer. Protein dephosphory-
lation was carried out in 50-l reactions consisting of 50 g of
cell protein and 10 units of calf intestinal phosphatase. The
reactions were incubated at 37 °C for 30 min followed by SDS-
PAGE and Western blotting.
Immunoprecipitation Assays—V5-tagged IRAK1 and IRF6
were immunoprecipitated from transfected HEK293T cells by
incubating 1 mg of cell lysate (in 1 ml lysis buffer) with 1 g of
anti-V5 antibody and 20 l of Protein G-Sepharose for 4 h at
4 °Cwith constantmixing. The beads were washed 4 times with
lysis buffer and then subjected to electrophoresis on 10%
NuPAGE gels followed by Western blotting.
ImmunofluorescentStainingandConfocalMicroscopy—HEK293T
cells, which had been seeded onto glass coverslips prior to
transfection, were fixed with 4% paraformaldehyde (30 min),
solubilizedwith 0.1%TritonX-100 (5min), and then blocked in
5% goat serum (60min), all at room temperature. The cells were
subsequently stained overnight (at 4 °C) with a rabbit anti-IRF6
antibody. After three washes with PBS, the cells were probed
with an Alexa Fluor 488-conjugated goat anti-rabbit IgG anti-
body for 60 min (at room temperature). The cells were washed
3 times with PBS and finally mounted on glass microscope
slides using ProLongGold Antifade reagent containing DAPI.
Mounted coverslips were allowed to cure for 24 h in the dark
before images of the cells being acquired on an Olympus
FV1000 scanning confocal microscope. No anti-IRF6 staining
was apparent in HEK293T cells transfected with empty vector
only.
Statistical Analysis—Data combined from three or more
independent experiments are given as the means S.E. Statis-
tical analyses were performed using GraphPad Prism software
Version 6.01 (GraphPad Software, La Jolla, CA). Differences
between two groups were evaluated using Student’s t test. For
multiple comparisons, statistical analysis was performed using
a one-way analysis of variance and then the Sidak’s orDunnett’s
test as a post-hoc test. A p value 0.05 was considered to be
statistically significant.
RESULTS
Activation of IRF6 Trans-activator Function by IRAK1—
Prior studies have demonstrated that IRAK1 mediates, either
directly or indirectly, IRF5 and IRF7 activation in response to
MyD88-dependent TLR signaling in myeloid cells (39–42).
Given that phylogenetic analysis had also revealed that IRF6
wasmost closely related to IRF5 (43), we investigated the ability
of IRAK1 to activate IRF6. IRF6 activity was assayed using an
IFN gene promoter reporter plasmid, whichwas activated in a
concentration-dependent manner by IRF6 (Fig. 1A). IRF6
IRF6 Differentially Regulates TLR2 Responses
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trans-activator function was strongly potentiated in a kinase-
dependentmanner by IRAK1 (Fig. 1B). Its trans-activator func-
tion was also potentiated by IRAK2 (Fig. 1C) and MyD88 (Fig.
1D) but not by TBK1 (Fig. 1E) or TRIF (data not shown). As an
indicator of some promoter specificity, IRF6, either alone or
when co-expressed with IRAK1, did not trans-activate the pro-
moter from the IFN4 gene in this assay (Fig. 1F), although
IRF3 robustly synergized with TBK1 in activating the IFN4
reporter.
The ability of IRF6 to interact with IRAK1 was also investi-
gated through co-immunoprecipitation assays. An IRF6 dou-
blet was detected when lysates of transfected HEK293T cells
were subjected to Western blotting (Fig. 1, G and H), with the
upper band reported to arise from the cell cycle-dependent
phosphorylation of IRF6 (27, 31). That the upper band is due to
IRF6 phosphorylation was also confirmed here by an in vitro
dephosphorylation assay (Fig. 1G). As previously shown (44),
several electrophoretically distinct forms of wild type, but not
kinase-dead (KD), IRAK1 were also apparent (Fig. 1H, bottom
panel). IRF6 interacted with the IRAK1 KD mutant, either
directly or as part of a complex (Fig. 1I). In contrast, the co-
immunoprecipitation of IRF6 with wild type IRAK1 was often
largely undetectable, suggesting that IRF6 interacted only tran-
siently with active IRAK1. IRF6 did not co-immunoprecipitate
with ectopically expressed MyD88 (data not shown). Collec-
tively, these data suggest that IRF6maymediate IRAK1-depen-
dent inflammatory gene expression in response to MyD88-de-
pendent TLR activation in epithelial cells.
IRF6 andTLR2-inducibleChemokineGeneExpression inEpi-
thelial Cells—To investigate whether IRF6 may mediate IFN
or chemokine gene expression in response to IRAK1-depen-
dent TLR signaling in epithelial cells, we screened several
human cell lines for IRF6 expression. IRF6mRNAwas detected
in the non-transformed oral epithelial cell line, OKF6/TERT-2
FIGURE1.Activationof IRF6by IRAK1.A, HEK293T cellswere transfectedwith an IFNgenepromoter reporter plasmid in thepresenceof increasing amounts
of an expression vector encoding HA-tagged IRF6. Gene reporter activity was measured 24 h post-transfection and is shown as the -fold increase over cells
transfectedwith empty vector. Data fromn3experiments arepresented as themean S.E.B–E, HEK293T cellswere transfectedwith an IFNgenepromoter
reporter plasmid together with expression vectors encoding the indicated proteins. Gene reporter activity wasmeasured 24 h post-transfection and is shown
as the -fold increase over cells transfected with empty vector. Data from n 3 experiments are presented as themean S.E. (** p 0.01). F, HEK293T cells
were transfectedwith an IFN4 gene promoter reporter plasmid togetherwith expression vectors encoding the indicated proteins. Gene reporter activitywas
measured 24 h post-transfection and is shown as the -fold increase over cells transfectedwith empty vector. Data from n 3 experiments are presented as the
mean  S.E. (**  p  0.01). G, lysates of HEK293T cells transiently expressing HA-IRF6 were incubated in the absence and presence of calf intestinal
phosphatase (CIP) followed byWestern blottingwith an anti-HA antibody. Data are representative of n 4 experiments.H, lysates of HEK293T cells transiently
expressing the indicated proteins were subjected to Western blotting. The IRF6 doublet represents phosphorylated (upper band, denoted by p) and non-
phosphorylated (lower band, denoted by np) forms. I, V5-taggedwild type and kinase-dead IRAK1were immunoprecipitated from the cell lysates inH followed
by Western blotting. Data are representative of n 3 experiments.
IRF6 Differentially Regulates TLR2 Responses
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(hereafter referred to as OKF6 cells) (Fig. 2A); lower levels were
also detected in the gastric cancer epithelial cell lines, AGS and
MKN28, and the intestinal cancer epithelial cell line, HT-29
(Fig. 2A). Consistent with the concept that, by comparison to
other IRF family members, IRF6 is preferentially expressed in
epithelial cells (26–30), IRF6 mRNA was not detected in
human bloodmonocytes or inmonocyte-derivedmacrophages
(MDM) (Fig. 2A). IRF6 protein expression in OKF6 cells and its
absence in HEK293T cells was confirmed by Western blotting
(Fig.2A, inset);additionally,phosphorylatedandnon-phosphor-
ylated forms of IRF6 were detected. IRF6 expression levels in
OKF6 cells were also compared with those of IRF3, IRF5, and
IRF7 (Fig. 2B). IRF6 mRNA levels were 5–10-fold higher than
those of IRF3 and up to 100-fold higher than those of IRF5 and
IRF7. A similar analysis revealed that IRAK1 was expressed at
levels up to 10-fold higher than IRAK2 (Fig. 2C).
OKF6 cells expressed mRNA for TLR1–9, except TLR8 (Fig.
2D). TLR2, which recognizes structural components of both
Gram-positive and Gram-negative bacteria, including lipopep-
tides and lipoteichoic acid (10, 11), was most abundantly
expressed, at least at the mRNA level. Therefore, we tested the
ability of the lipopeptide, FSL-1, to induce IFN and chemokine
gene expression. IFN gene expression was not induced by
FSL-1 (data not shown), nor was it induced by ligands for TLR7
(imiquimod) or TLR9 (CpG DNA) (data not shown). However,
FSL-1 did robustly up-regulate CCL5 (Fig. 2E) andCXCL8 gene
expression (Fig. 2F). FSL-1-inducible CCL5 gene expression
was markedly more sustained than CXCL8 expression.
IRAK1 Is Required for TLR2-inducible CCL5 and CXCL8
Gene Expression in Epithelial Cells—The importance of IRAK1
for the induction ofCCL5 andCXCL8 gene expression byTLR2
signaling in OKF6 cells was examined by gene silencing. Trans-
fection of the cells with IRAK1-targeting siRNAs markedly
reduced IRAK1 expression (Fig. 3A) without affecting IRAK2
(data not shown). Knock-down of IRAK1 expression greatly
inhibited (70%) FSL-1-inducible CCL5 gene expression (Fig.
3B). Similarly, the induction of CXCL8 gene expression was
also strongly inhibited by IRAK1 knock-down (Fig. 3C). These
data, therefore, establish IRAK1 as an essential mediator of
TLR2-inducible CCL5 and CXCL8 gene expression in OKF6
cells.
IRF6 Is Required for TLR2-inducible CCL5 Gene Expression
in Epithelial Cells—We next used the same approach to deter-
mine the importance of IRF6 in the FSL-1-mediated induction
of CCL5 and CXCL8 gene expression. Transfection of an IRF6-
targeting siRNA reduced levels of IRF6 mRNA (Fig. 4A) and
protein (Fig. 4B) in OKF6 cells without significantly affecting
IRF3, IRF5, and IRF7 mRNA levels (data not shown). Knock-
down of IRF6 expression inhibited FSL-1-inducible CCL5 gene
expression by 50% (Fig. 4C). In contrast, the induction of
CXCL8 gene expression by FSL-1 was not significantly affected
by IRF6 knock-down (Fig. 4D).
Co-immunoprecipitation experiments failed to detect an
FSL-1-inducible interaction between endogenous IRF6 and
IRAK1 in OKF6 cells (data not shown). This was not unex-
pected given that the data in Fig. 1I suggest IRF6 and IRAK1
interact only transiently. Therefore, the potential for IRF6 to
mediate the IRAK1-dependent regulation of CCL5 gene
expression was further assessed through gene promoter
reporter assays. Ectopic IRF6 expression was not sufficient to
activate the CCL5 reporter (Fig. 4E). However, IRAK1 co-ex-
pression resulted in the robust trans-activation of the reporter
by IRF6; IRAK1 only weakly activated the reporter in the
absence of IRF6 (Fig. 4E). In contrast, IRAK1 alone strongly
activated theCXCL8 reporter, and this effectwas onlymodestly
increased by the co-expression of IRF6 (Fig. 4F). Taken
together, these findings are consistent with IRF6 mediating a
sub-set of TLR2/IRAK1-dependent inflammatory responses in
epithelial cells.
Identification of Ser-413 and Ser-424 as Putative Regulatory
Phosphorylation Sites in IRF6—Little is known about how the
trans-activator function of IRF6 is regulated. The inducible-
FIGURE 2. Expression analysis of specific TLR signaling proteins and
chemokine gene induction in epithelial cells. A, IRF6 mRNA expression
levels in the indicated cellsweremeasuredby real-timePCR. Expression levels
are relative to those of the endogenous control gene, HPRT. Data from n 3
experiments are presented as the mean  S.E. (ND  not detected). Inset,
lysates ofHEK293TandOKF6cellswere subjected toWesternblottingwith an
anti-IRF6 antibody. Phosphorylated (upper band, denoted by p) and non-
phosphorylated (lower band, denoted by np) forms of IRF6 are indicated. B–D,
the expression levels of IRF3, IRF5, IRF6, and IRF7 (B), IRAK1 and IRAK2 (C), and
TLR1–9 (D) in OKF6 cells were measured by real-time PCR. Expression levels
are relative to those of HPRT. Data from n 3 experiments are presented as
themean S.E. E and F, OKF6 cellswere stimulatedwith FSL-1 (100ng/ml) for
the times indicated. CCL5 (E) and CXCL8 (F) mRNA levels were measured by
real-time PCR and are shown as the -fold increase relative to mock-treated
cells. Data fromn 3 experiments are presented as themean S.E. (** p
0.01).
IRF6 Differentially Regulates TLR2 Responses
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phosphorylation of specific serine residues has been shown to
play a critical role in regulating the trans-activator functions of
other IRFs (14, 45–48). To identify potential regulatory phos-
phorylation sites in IRF6, the regions of IRF3, IRF5, and IRF7
that contain such sites (e.g. Ser-437 and Ser-446 in IRF5) were
aligned with the corresponding region in IRF6 (Fig. 5A). Ser-
413 and Ser-424 in the C-terminal domain of IRF6 were con-
served in IRF3, IRF5, and IRF7 and were also conserved in the
mouse, rat, bovine, chicken, and zebrafish IRF6 orthologs (data
not shown).
The importance of Ser-413 and Ser-424 for the regulation of
IRF6 trans-activator function by IRAK1 was investigated by
mutating, either individually or together, these residues to ala-
nine. As shown in Fig. 5B, the mutation of Ser-413 to alanine
partially abrogated IRAK1-mediated IRF6 activation. By con-
trast, IRF6 S424A and the IRF6 mutant in which both Ser-413
and Ser-424 had been replaced by alanine, IRF6 S413A/S424A,
were completely inactive in this assay (Fig. 5B). Co-immuno-
precipitation experiments revealed that the IRF6 serine-to-ala-
nine mutants, IRF6 S413A and IRF6 S413A/S424A, still inter-
acted with IRAK1 at comparable levels to wild type IRF6 (Fig.
5C). Therefore, although Ser-413 and Ser-424 do not appear to
be important for the interaction of IRF6 with IRAK1, they are
critical for optimal IRAK1-mediated IRF6 activation.
As mentioned earlier, cell cycle-dependent phosphorylation
of IRF6 results in the detection of an IRF6 doublet in Western
blots of cell lysates (27, 31). Significantly, an IRF6 doublet was
still detected after the mutation of Ser-413 and/or Ser-424 to
alanine (Fig. 5C, bottom panel), thus suggesting these residues
are distinct from the site(s) that is phosphorylated in response
to growth factors.
Mutation of Ser-413 and Ser-424 to Glutamic Acid Results in
Constitutive IRF6 Activation—The involvement of Ser-413 and
Ser-424 in the regulation of IRF6 trans-activator function was
FIGURE 3. IRAK1-dependent regulation of CCL5 and CXCL8 gene expres-
sion by TLR2. A–C, OKF6 cells were transfected with a control non-targeting
(	) siRNA or two separate IRAK1-targeting (
) siRNAs. Forty-eight hours
post-transfection IRAK1 mRNA levels were measured by real-time PCR (A).
IRAK1mRNA levels in cells transfectedwith the control siRNAwere arbitrarily
given a value of 100%. B–C, the cells were stimulated with FSL-1 (100 ng/ml)
for the times indicated. CCL5 (B) and CXCL8 (C) mRNA levels were measured
by real-time PCR and are shown as -fold increase relative to mock-treated
cells. Data fromn 3 experiments are presented as themean S.E. (** p
0.01; * p 0.05).
FIGURE 4. IRF6-dependent regulation of CCL5 gene expression by TLR2.
A–D, OKF6 cells were transfected with a control non-targeting (	) or IRF6-
targeting (
) siRNA. Forty-eight hours post-transfection IRF6 mRNA levels
were measured by real-time PCR (A). IRF6 mRNA levels in cells transfected
with the control siRNA were arbitrarily given a value of 100%. B, cell lysates
were subjected to Western blotting with anti-IRF6 and anti-HSP90 (loading
control) antibodies. C andD, the cells were stimulatedwith FSL-1 (100 ng/ml)
for the times indicated. CCL5 (C) and CXCL8 (D) mRNA levels were measured
by real-time PCR and are shown as -fold increase relative to mock-treated
cells. Data from n 3 experiments are presented as themean S.E. (* p
0.05). E and F, HEK293T cells were transfected with a CCL5 (E) or CXCL8 (F)
gene promoter reporter plasmid together with expression vectors encoding
the indicated proteins. Gene reporter activity was measured 24 h post-trans-
fection and is shown as -fold increase over cells transfected with empty vec-
tor. Data from n 4 experiments are presented as themean S.E. (** p
0.01).
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next addressed bymutating, either individually or together, the
two residues to the phosphomimetic, glutamic acid. Mutation
of Ser-413, Ser-424, or both Ser-413 and Ser-424 to glutamic
acid increased IRF6 activity toward the IFN gene promoter
reporter 15-, 5-, and 40-fold, respectively (Fig. 6A). The ability
of IRAK1 to increase further the activities of these IRF6 gain-
of-function mutants was also tested. The activity of the IRF6
S413Emutant was enhanced by IRAK1 co-expression, whereas
those of IRF6 S424E and IRF6 S413E/S424E were not (Fig. 6B).
Notably, in the absence of IRAK1, the activity exhibited by the
IRF6 S413E mutant was 3-fold higher than that when wild type
IRF6 was co-expressed with IRAK1, whereas the activity of
the IRF6 S424E mutant was comparable to that exhibited by
wild type IRF6 after co-expression with IRAK1 (Fig. 6B).
As was the case for wild type IRF6 and the IRF6 S413A/
S424A mutant (Fig. 5C), an IRF6 S413E/S424E doublet was
detected byWestern blotting (Fig. 6C, bottompanel). Themore
slowly migrating form of the IRF6 S413E/S424E mutant was
absent when the cell lysates were treated with calf intestinal
phosphatase before electrophoresis (data not shown).
Given that dimerization is a key step in the activation and
nuclear translocation of IRFs (12, 13, 45, 47, 49), the effects of
mutating Ser-413 and Ser-424 to glutamic acid on IRF6
dimerization were assessed. V5- and HA-tagged versions of
wild type IRF6 and IRF6 S413E/S424E were ectopically
expressed, and dimerization was then evaluated through co-
immunoprecipitation experiments. The IRF6 S413E/S424E
mutant exhibited increased levels of spontaneous dimerization
(Fig. 6C), consistent with its greatly enhanced trans-activator
FIGURE 5. Identification of regulatory phosphorylation sites in IRF6. A,
schematic representation of IRF6 (DBD  DNA binding domain; IAD  IRF
association domain; CTD C-terminal domain). Partial amino acid sequence
alignment of human IRF6 with IRF3, IRF5, and IRF7 is shown. Serine residues
that are conserved between all four IRFs are shown in bold. B, HEK293T cells
were transfectedwith an IFNgenepromoter reporter plasmid togetherwith
expression vectors encoding the indicated proteins (IRF6 S413A, Ser-413
replaced by alanine; IRF6 S424A, Ser-424 replaced by alanine; IRF6 2SA, Ser-
413 and Ser-424 replaced by alanine). Gene reporter activity was measured
24 h post-transfection and is shown as -fold increase over cells transfected
with empty vector.Data fromn3experiments arepresentedas themean
S.E. (**  p  0.01). C, HEK293T cells transiently expressing the indicated
proteins were lysed 24 h post-transfection. Wild type and kinase-dead IRAK1
were immunoprecipitated (IP) from the lysates using anti-V5 antibodies fol-
lowed by Western blotting with anti-HA and anti-V5 antibodies. Phosphory-
lated (upper band, denoted by p) and non-phosphorylated (lower band,
denoted by np) forms of IRF6 are indicated. Cell lysates were subjected to
Western blotting with an anti-HA antibody. Data are representative of n 3
experiments.
FIGURE6.Phosphomimetic-mediatedactivationof IRF6.A andB, HEK293T
cellswere transfectedwith an IFNgenepromoter reporter plasmid together
with expression vectors encoding the indicated proteins (IRF6 S413E, Ser-413
replacedby glutamic acid; IRF6 S424E, Ser-424 replacedby glutamic acid; IRF6
2SE, Ser-413 and Ser-424 replaced by glutamic acid). Gene reporter activity
wasmeasured 24 h post-transfection and is shown as -fold increase over cells
transfected with empty vector. Data from at least n  3 experiments are
presented as the mean S.E. (** p 0.01, * p 0.05). C, HEK293T cells
transiently expressing the indicated proteins were lysed 24 h post-transfec-
tion. V5-IRF6 and V5-IRF6 S413E/S424E were immunoprecipitated (IP) using
anti-V5 antibodies followed by Western blotting with anti-HA and anti-V5
antibodies. Phosphorylated (upper band, denoted by p) and non-phosphory-
lated (lower band, denoted by np) forms of IRF6 are indicated. Cell lysates
were subjected to Western blotting with an anti-HA antibody. Data are rep-
resentative of n  3 experiments. D, HEK293T cells were transiently trans-
fected with an expression vector encoding IRF6 S413E/S424E. Twenty-four
hours later the cells were treated with 20 ng/ml leptomycin B (
LMB) for 60
min, or left untreated (	LMB). The cells were stained with an anti-IRF6 anti-
body (green staining); nuclei were stained with DAPI (blue staining). Data are
representative of n 5 experiments.
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function (Fig. 6A). Despite its strong trans-activator function,
consistent nuclear localization of IRF6 S413E/S424E was not
observed (Fig. 6D). To test whether this may have been due to
its rapid nuclear export, the cells were treated with the nuclear
export inhibitor, leptomycin B (50). Treatment with the inhib-
itor resulted in partial IRF6 S413E/S424E nuclear localization
(Fig. 6D). This not only suggests that IRF6 nuclear translocation
is highly dynamic, but it may also involve mechanisms in addi-
tion to IRF6 phosphorylation.
Ser-413 and Ser-424 Are Important for the IRAK1-mediated
Trans-activation of the CCL5 Promoter by IRF6—The creation
of loss-of-function and gain-of-function IRF6 mutants (i.e.
IRF6 S413A/S424A and IRF6 S413E/S424E, respectively)
allowed us to further investigate themechanism underlying the
IRAK1-mediated regulation of CCL5 gene expression by IRF6.
Ser-413 and Ser-424 were required for the synergistic activa-
tion of the CCL5 gene promoter reporter by IRF6 and IRAK1
(Fig. 7A). The IRF6 S413E/S424Emutant only weakly activated
the CCL5 reporter in the absence of co-expressed IRAK1 (Fig.
7B), which differed from its robust and IRAK1-independent
activation of the IFN gene promoter reporter (Fig. 6B). There-
fore, phosphorylation of Ser-413 and Ser-424 is likely to be nec-
essary, but not sufficient, for the optimal induction of CCL5
gene expression by IRF6.
DISCUSSION
IRF6 is a critical regulator of epithelial cell proliferation and
differentiation (27–29, 31, 32) and is important for epithelial
barrier function (28, 29). Data presented herein also positions
IRF6 as a key regulator of TLR2-inducible chemokine (CCL5)
gene expression in epithelial cells. Our findings thus reveal new
insights into the molecular mechanisms through which epithe-
lial cells actively contribute to the host immune response to
pathogens.
A role for IRF6 inMyD88-dependent TLR signaling was sug-
gested by our finding that IRAK1, as well as MyD88, but not
TBK1 or TRIF, strongly potentiated IRF6 trans-activator func-
tion. Furthermore, the ability of IRF6 to form a complex, either
directly or indirectly, with IRAK1 suggests that the entry point
for IRF6 in the MyD88-dependent TLR signaling pathway is
likely to be at the level of IRAK1. IRF5 and IRF7, which similarly
operate downstream of IRAK1 in the MyD88-dependent path-
way, are key mediators of the inflammatory responses elicited
by TLRs in myeloid cells (20–22). Not only does IRF6 expres-
sion appear to be restricted to epithelial cells (26–30), butmore
widespread analysis of gene expression data via the BioGPS
portal suggested that IRF6 is the only epithelial-restricted IRF
family member. As such, IRF6 may uniquely regulate specific
MyD88-dependent TLR responses in epithelial cells.
Accordingly, we investigated a possible functional relation-
ship between IRF6 and IRAK1 in the context of TLR2 signaling
in human oral epithelial cells (e.g. OKF6 cells). TLR2 is a key
mediator of host defense as it recognizes conserved molecular
patterns associated with Gram-positive and Gram-negative
bacteria (11, 51–53). Significantly, although IRF6 and IRAK1
were important for the up-regulation of chemokine gene
expression by TLR2, their contributions were chemokine-spe-
cific, at least for CCL5 and CXCL8. IRAK1 was required for the
induction of both CCL5 and CXCL8 gene expression. In con-
trast, whereas TLR2-inducible CCL5 gene expression was also
heavily reliant on IRF6, CXCL8 expression was induced inde-
pendently of IRF6. In line with these findings, the CCL5 pro-
moter was robustly activated by IRF6 and IRAK1 co-expres-
sion, whereas IRAK1 strongly activated the CXCL8 promoter
independently of IRF6. Hence, IRAK1 likely mediates TLR2-
inducible CCL5 gene expression, at least in part, by promoting
the activation of IRF6. The differing effect of IRF6 in regulating
CCL5 versus CXCL8 gene expression provides a molecular
mechanism for the differential regulation of specific chemo-
kines downstreamof TLR2, thereby enabling distinct responses
to be elicited. CXCL8 is a key regulator of neutrophil trafficking
(54), whereas CCL5 mediates the trafficking and homing of
various leukocyte cell populations, including T-cells, macro-
phages, and eosinophils (55). Our findings, therefore, place
IRF6 in the signaling framework as a likely mediator of CCL5-
dependent leukocyte recruitment to sites of epithelial infection.
IRF6 also activated the IFN promoter, suggesting that this
gene may also be an IRF6 target. Although we found that
MyD88-selective TLR agonists, including those of TLR7 and
TLR9, did not induce IFN expression inOKF6 cells, it remains
possible that this response does occur in other epithelial cell
types as well as in vivo. Similarly, a role for IRF6 in regulating
IFN gene expression cannot be excluded.
The inducible phosphorylation of serine residues has been
shown to play a critical role in regulating the activation of sev-
eral IRFs (14, 45–48, 56). A two-step, sequential phosphoryla-
FIGURE7.EffectsofmutatingSer-413andSer-424onthe trans-activation
of the CCL5promoter by IRF6.A and B, HEK293T cells were transfectedwith
a CCL5 gene promoter reporter plasmid together with expression vectors
encoding the indicated proteins (IRF6 2SA, Ser-413 and Ser-424 replaced by
alanine; IRF6 2SE, Ser-413 and Ser-424 replaced by glutamic acid). Gene
reporter activity was measured 24 h post-transfection and is shown as -fold
increase over cells transfected with empty vector. Data from n  3 experi-
ments are presented as the mean S.E. (** p 0.01).
IRF6 Differentially Regulates TLR2 Responses
JULY 11, 2014•VOLUME 289•NUMBER 28 JOURNAL OF BIOLOGICAL CHEMISTRY 19765









tion model has been proposed for IRF3 activation (57). In this
model, the phosphorylation of serine residues in “site 2” (e.g.
Ser-396 in IRF3) is needed to alleviate autoinhibition and allow
interaction with the co-activator, CBP/p300; it also facilitates
the phosphorylation of residues in “site 1” (e.g. Ser-386 in IRF3),
which is required for IRF dimerization (57). We show here that
Ser-413 and Ser-424, which correspond, respectively, to Ser-
386 and Ser-396 in IRF3, are important for IRF6 function.
Although not formally demonstrated, the marked increase in
IRF6 trans-activator function by the phosphomimeticmutation
of Ser-413 and Ser-424 to glutamic acid argues that they are
regulatory phosphorylation sites. Thus, the trans-activator
function of IRF6 may likewise be regulated by a two-step,
sequential phosphorylation mechanism in which Ser-424
serves as a “gatekeeper” phosphorylation site.
Importantly, our data strongly suggest that Ser-424 is an
IRAK1-regulated phosphorylation site, although it has not yet
been established if IRAK1 directly regulates the phosphoryla-
tion of Ser-424 or does so by activating another kinase.
Although Ser-413 is likewise required for maximal IRAK1-me-
diated IRF6 activation, IRAK1 did not further enhance the
trans-activator function of the IRF6 S424E mutant. Nonethe-
less, phosphorylation of Ser-413 would be expected to be
important for maximal IRF6 activity in view of the activating
effect of its phosphomimetic mutation on IRF6 trans-activator
function. The activation of IRF7 byTLR7/9 signaling appears to
be mediated by both IRAK1 and IKK (inhibitor of nuclear
factor B kinase ) (39–41, 58). By analogy, IRF6 may be reg-
ulated in a similar manner, with IRAK1 specifically regulating,
either directly or indirectly, the phosphorylation of Ser-424 and
another kinase then phosphorylating Ser-413.
The phosphomimetic mutation of Ser-424 and Ser-413
strongly enhanced IRF6 dimerization and trans-activator func-
tion; however, it did not result in demonstrable nuclear local-
ization. Nuclear translocation of the IRF6 S413E/S424Emutant
was apparent after treatment with the nuclear export inhibitor,
leptomycin B. This would suggest that IRF6 is subject to tightly
regulated cytoplasmic-nuclear shuttling. Consequently, addi-
tional posttranslational modifications (e.g. ubiquitination) may
also be necessary for sustained IRF6 nuclear translocation.
The cooperation between IRFs and NF-B is necessary for
the optimal expression of some inflammatory genes (59–61).
This may also be the case for the regulation of CCL5 gene
expression by IRF6. Despite the IRF6 S413E/S424E mutant
being highly active, it was largely ineffective in trans-activating
the CCL5 promoter; the co-expression of IRAK1, which can
also activate endogenous NF-B, was necessary for robust acti-
vation of the CCL5 promoter. Virus-induced CCL5 gene
expression in alveolar epithelial cells was reported to require
both IRF andNF-B activity (15). Therefore, optimal induction
of CCL5 gene expression by IRAK1-mediated TLR2 signaling
in epithelial cells may require functional cooperation between
IRF6 and NF-B.
In addition to its trans-activator function, phosphorylation
also appears to regulate the cell cycle-dependent degradation of
IRF6 (31). However, neither Ser-413 nor Ser-424 is likely to be
the phosphorylation site(s) that targets IRF6 for proteasomal
degradation as theirmutation did not affect IRF6 protein levels.
The phosphorylation-mediated regulation of IRF6 trans-acti-
vator function and degradation are thus likely to be regulated in
a stimulus-dependent manner by distinct signaling pathways.
In summary, this study has uncovered a non-redundant role
for IRF6 in differentially regulating TLR2-elicited chemokine
responses in epithelial cells. Given its role in also regulating
epithelial cell proliferation and differentiation, IRF6 may act as
a pivotal nexus for distinct signaling pathways and regulate
both the barrier and inflammatory functions of epithelial cells.
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